Retatrutide's Triple-Receptor Profile Retatrutide's glucagon receptor activity accelerates lipolysis and raises resting energy expenditure
Whether compounded preparations produce the same side effect profile cannot be confirmed for the specific formulations used by any individual pharmacy, as those formulations haven't been reviewed by the FDA
3 Cardiac arrhythmias affected 2-11% of participants on retatrutide versus 2% on placebo, but none were serious
This makes Retatrutide the first medication to achieve surgical level weight loss through pharmaceutical intervention alone
[1] [3] For many people, fatigue begins to improve as the body adapts to the medication's effects
Key metrics (e.g., BMI, blood pressure, biometric results (HDL/LDL, triglycerides), large waist size, exercise/diet levels) could be weighted and scored to assign cutoff thresholds for risk tiers that receive different levels of coverage